Clinical Trials on Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Total 1065 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Recurrent Disease | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase of Disease | Chronic Phase of Disease

United States, Germany, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Emory University

Terminated

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Primary Myelofibrosis | Thrombocytopenia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center

Active, not recruiting

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...

United States
Stanford University

Terminated

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Primary Myelofibrosis | Myelofibrosis | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Non-Hodgkin Lymphoma | Blast... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | B Acute Lymphoblastic Leukemia With t(9;22)(q34... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States
National Cancer Institute (NCI)

Terminated

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
Thomas Jefferson University

Completed

A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Disease | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Adult B Acute Lymphoblastic... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Unspecified Childhood Solid Tumor, Protocol Specific | Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
M.D. Anderson Cancer Center

Active, not recruiting

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia With BCR-ABL1

United States
National Cancer Institute (NCI)

Terminated

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Versailles Hospital
University Hospital, Bordeaux; Maisonneuve-Rosemont Hospital

Completed

OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) (OPTIM-DASA)

Chronic Myelogenous Leukemia, BCR/ABL Positive

France, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Accelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | t(9;22) | BCR-ABL1 Fusion Protein Expression

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic... and other conditions

United States
Pfizer

Completed

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

France, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase (CML0912)

Chronic Phase Philadelphia Positive | BCR-ABL Positive | Chronic Myeloid Leukaemia

Italy
Mansoura University

Completed

Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment

CML, Chronic Phase | Chronic Myelogenous Leukemia, BCR-ABL Positive

Egypt
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pfizer

Terminated

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White Cells

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia... and other conditions

United States
City of Hope Medical Center

Withdrawn

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Hematopoietic Cell Transplantation Recipient | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
University of Milano Bicocca
IRCCS San Raffaele

Completed

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy

Leukemia | BCR-ABL Positive | Myelogenous | Chronic

Italy
M.D. Anderson Cancer Center

Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Active, not recruiting

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Lymphoblastic Lymphoma | Childhood Acute Myeloid Leukemia in Remission | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Chronic Myelomonocytic Leukemia | Recurrent Disease | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Accelerated Phase of Disease | Chronic Phase of Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States

Clinical Trials on Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations